Baidu
map

Cell Death Dis:活性氧(ROS)的损伤与保护的博弈决定心肌缺血/再灌注的命运

2014-06-26 MedSci MedSci原创

6月19日,自然出版集团子刊Cell Death and Disease在线发表了健康科学研究所杨黄恬研究组题为 “Concentration-dependent wrestling between detrimental and protective effects of H2O2 during myocardial ischemia/reperfusion” 的最新研究成果,揭示了H

MedSci临床研究解读:

MedSci临床研究解读课程上线啦,看看这篇研究有哪些地方值得学习,还有哪些内容值得深入挖掘。请点击下方视频链接,观看MedSci学术对此文章的点评。





研究内容阅读:

6月19日,自然出版集团子刊Cell Death and Disease在线发表了健康科学研究所杨黄恬研究组发表了最新研究成果,揭示了H2O2在心肌缺血复灌(ischemia/reperfusion, I/R)过程中浓度依赖的损伤与保护的双重作用和不同的作用机制。

心肌梗塞后及时恢复缺血区的血供(再灌注)是挽救缺血心肌的必需步骤,但该过程伴随着严重再灌注损伤的发生。再灌注初期活性氧(reactive oxygen species, ROS)的大量释放被认为是造成这一损伤的主要因素之一。然而,ROS也作为启动者介导了缺血预处理(ischemic preconditioning, IPC)和后处理(ischemic postcondition, IPoC)等措施对抗心肌I/R损伤的保护作用。为了解释ROS 这种相互矛盾的双重作用,研究者提出了一种假设,即低浓度ROS 作为第二信使参与了心肌保护作用,而高浓度ROS 则导致细胞损伤,但如何界定ROS 起损伤或保护作用浓度界限目前尚无明确的研究,而且该理论无法完美解释众多应用抗氧化剂的临床实验没有显著心肌保护作用的事实。

博士研究生王志华、刘金龙等在杨黄恬研究员的指导下发现H2O2PC和PoC在10-100 mmol/L浓度依赖地激活RISK信号通路、抑制其下游的糖原合成酶激酶(glycogen synthase kinase, GSK)3-b活性,进而改善I/R后心功能;而低浓度(1-3 mmol/L)及高浓度(1 mmol/Lol/L) H2O2他则通过不同的机制加重了I/R后心功能不全。低浓度H2O2PC和PoC (1-3 mmol/L) 通过进一步上调心肌I/R导致的ER stress加重了I/R后心肌损伤,该效应在3 mmol/L H2O2处理下达到平台期;而高浓度H2O2 (≧100 mmol/L) 则通过促进氧化应激反应加重I/R后心肌损伤。研究发现证明了浓度是决定ROS不同作用的重要因素之一,揭示了ROS导致心肌I/R损伤和保护作用的浓度 阈值和其内在机制,其最终表现是不同浓度ROS启动/激活的损伤与保护通路博弈的结果。研究发现还为解释ROS矛盾作用的机理提供了新的视角,并为开发基 于ROS的缺血性心脏病的治疗措施提供了新的实验证据。

此研究得到了国家自然科学基金委和国家科技部973项目的资助。

原始出处

Wang ZH, Liu JL, Wu L, Yu Z, Yang HT.Concentration-dependent wrestling between detrimental and protective effects of H2O2 during myocardial ischemia/reperfusion.Cell Death Dis. 2014 Jun 19;5:e1297

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-11-09 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-08-09 cjyisheng

    困扰大家的问题终于露出了冰山一角,很好的研究。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 徐岩
  6. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 lsndxfj
  7. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1959089, encodeId=baa1195908999, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Nov 09 09:23:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868846, encodeId=89a7186884607, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 11 00:23:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11009, encodeId=8bfd11009f6, content=困扰大家的问题终于露出了冰山一角,很好的研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=241, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Sat Aug 09 20:12:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011895, encodeId=70452011895ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 09 18:23:00 CST 2015, time=2015-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301366, encodeId=f4341301366cc, content=<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363971, encodeId=73dc13639e1e3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396844, encodeId=1698139684459, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531382, encodeId=f56c15313821d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Jun 28 00:23:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 cy0328

相关资讯

DIABETES CARE:糖尿病患者冠脉狭窄风险明显升高

    一项最新研究显示,我国早期糖尿病患者中无心肌缺血症状者,其发生冠脉狭窄的风险明显升高。血糖水平是糖尿病患者发生冠脉狭窄的独立危险因素。研究由上海交通大学医学院附属瑞金医院宁光等人进行,2013年3月5日在线发表于《糖尿病护理》(Diabetes Care)杂志。   研究旨在评价无心肌缺血症状的中国成年糖尿病患者或糖尿病前期人群的冠脉狭窄风险。研究者从社

[OCC2013]稳定型冠心病的诊断策略:心肌是否缺血是决策之本

很重要一点,需要评估稳定型心绞痛的患者是否存在心肌缺血,心肌缺血的面积有多大。稳定型心绞痛患者的远期死亡率随缺血面积增大而增高,缺血面积的减少可显著降低死亡率,而血运重建较药物治疗在降低缺血面积方面更有效。既往评估缺血情况更多的是无创的运动负荷心电图试验、运动负荷超声、核素心肌显像等,但有很多患者在进入导管室前缺乏这些检查结果就直接进行冠脉造影进行评估,所幸目前临床上有了较好的在导管室中评估狭窄病

JAMA:用抗抑郁症药物治疗可降低精神刺激诱发的心肌缺血发生率

据发表在5月22/29日刊《美国医学会杂志》上的一则研究披露,在罹患稳定型冠心病及精神压力诱发的心肌缺血(MSIMI)患者中,与安慰剂相比,用抗抑郁药艾司西酞普兰治疗6周可降低MSIMI发生率。 根据文章的背景资料:“有一系列强有力的证据已经确认情绪压力是冠心病(CHD)及其它心血管事件的一个可能的触发因子” 。“在过去的30年中,对情绪苦恼与心肌缺血性活动[心肌血流量不足,常常会引起胸痛]之间

JAMA:艾司西酞普兰可显著减少精神刺激诱发的心肌缺血发生率

发表于《美国医学会杂志》5月22/29日刊在线版的一项研究显示,对于稳定型冠心病及精神紧张诱发的心肌缺血(MSIMI)患者,使用抗抑郁药艾司西酞普兰治疗6周与安慰剂相比,可降低MSIMI发生率。“已存在相当数量的有力证据证明情绪压力是冠心病(CHD)及其它心血管事件的潜在触发因子,”文章的背景信息写道。“在最近的30年中,对情绪苦恼与心肌缺血性活动[心肌血流量不足,常常会引起胸痛]之间的关系已经在

Eur Heart J:空气污染与急性冠脉综合症患者存活率有关

大量研究表明长期暴露于空气污染环境,特别是不溶性微粒,与心血管疾病发病有关。心肌缺血患者可能对空气污染更敏感。近期,伦敦卫生和热带医学学校的开展了相关研究,目的是应用英格兰和威尔士心肌缺血国家审计项目的相关资料明确心肌缺血患者所有病因导致的死亡率是否与长期暴露于空气污染环境有关,并进一步阐明空气污染暴露的程度对患者预后社会经济不平等的影响。结果显示,空气污染对心脏病患者所有原因导致的死亡率有影响。

Am J Cardiol:肺动静脉畸形患者可因反常栓子引发心肌缺血

  美国一项研究表明,在未治疗的肺动静脉畸形(PAVM)患者中,心脏缺血可由反常栓子通过PAVM进入冠状动脉而引发。论文于5月23日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究共纳入98例PAVM患者,其中84例接受PAVM栓塞治疗,其余14例患者因PAVM太小而无法实施栓塞。就心肺症状和心脏诊断病史通过电话对患者进行调查。   结果显示,6例

Baidu
map
Baidu
map
Baidu
map